ELAN.NYSEElanco Animal Health INC

Form 4: Elanco Director R. David Hoover Receives Equity Award

Sentiment:

Insider Transaction Report

📋All filings for Elanco Animal Health INC
🔒Login to Follow

Elanco Animal Health Inc. Director R. David Hoover was granted 10,314 shares of common stock as an annual equity award.

Summary

  • R. David Hoover, a Director of Elanco Animal Health Inc. (ELAN), acquired 10,314 shares of common stock.
  • This acquisition was a grant of deferred stock units, serving as an annual equity award for non-employee members of the Issuer's Board of Directors.
  • The transaction occurred on November 28, 2025, with a reported price of $0 per share.
  • Following this transaction, R. David Hoover directly beneficially owns 106,773 shares of common stock.
  • Additionally, he indirectly beneficially owns 210,000 shares through a Revocable Trust and 15,920 shares through the Suzanne A. Hoover Revocable Trust.

Sentiment

Score: 7

Explanation: The filing indicates a routine, positive event where a director receives an equity award, aligning interests with shareholders. It is a standard compensation practice and does not suggest any negative underlying issues for the company.

Positives

  • Director R. David Hoover received an annual equity award of 10,314 shares, which aligns his interests with those of the shareholders.
  • The grant is part of a standard compensation practice for non-employee directors, indicating stable corporate governance and a routine operational event.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

  • Shareholders: Increased alignment of a director's interests with shareholder value through equity ownership.

Key Dates

DateDescription
11/28/2025Transaction Date: Acquisition of 10,314 shares of Common Stock as an equity award.
12/02/2025Signature Date of the Form 4 filing by R. David Hoover's attorney-in-fact.

Recommendation

hold

This Form 4 filing reports a routine annual equity award to a non-employee director. Such transactions are standard compensation practices and do not typically provide new information that would significantly alter an investment thesis or warrant a change in stock recommendation. It primarily indicates ongoing alignment of director interests with shareholder value.

Keywords

Elanco Animal Health, ELAN, Form 4, Insider Transaction, Equity Award, Director Compensation, Stock Grant, R. David Hoover

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.